Regulation - Pricing

Filter

Current filters:

Pricing

Popular Filters

226 to 250 of 329 results

Europe's drug pricing sent askew by economic crash

22-08-2012

The European Union faced further fallout from the global financial crisis this year, and the region's…

EuropeHealthcarePharmaceuticalPricingRegulation

NICE says Roche's Avastin in breast cancer does not provide enough benefit to justify its cost

21-08-2012

The latest and final guidance from the UK's drug watchdog the National Institute for Health and Clinical…

AvastinBiotechnologyEuropeOncologyPharmaceuticalPricingRegulationRoche

AHF calls for Gilead's Quad HIV pill to be put on "prior authorization" status

19-08-2012

In what may be an unprecedented move on drug pricing and access, advocates from the AIDS Healthcare Foundation…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalPricingQuadRegulation

UK's NICE continues to back Amgen's Xgeva for most cancer patients with bone metastases

17-08-2012

In a final draft guidance issued today, (August 17), the National Institute for Health and Clinical Excellence…

AmgenBiotechnologyEuropePricingRegulationXgeva

Venezuelan govt increasing control over pharmaceutical sector

14-08-2012

Venezuela's national government has changed its policy with regard to the pharmaceutical sector. This…

FinancialGenericsPharmaceuticalPricingRegulationSouth America

UK's NICE delays decision on Roche's Zelboraf, asking for more information

10-08-2012

UK health care watchdog the National Institute for Health and Clinical Excellence (NICE) today (August…

EuropeOncologyPharmaceuticalPricingRegulationRocheZelboraf

NICE rejects Alimera's Iluvien for DMO in draft guidance

08-08-2012

In draft guidance published today (August 8) by UK drugs watchdog the National Institute for Health and…

Alimera SciencesEuropeIluvienOphthalmicsPharmaceuticalPricingRegulation

UK NICE draft guidance backs Servier's Procoralan for chronic heart failure

06-08-2012

The UK's drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in draft guidance…

Cardio-vascularEuropePharmaceuticalPricingProcoralanRegulationServier

UK's NICE to takeover role of assessing high-cost rare disease drugs

25-07-2012

In the UK, the role of assessing very high cost drugs for people who suffer with rare conditions, under…

BiotechnologyEuropePharmaceuticalPricingRare diseasesRegulation

UK NICE says final "yes" for Bayer's Xarelto to treat blood clots

24-07-2012

Confirming its final draft guidance last month (The Pharma Letter June 1), in final guidance published…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

J&J'S rilpivirine also proven for combination HIV product, says IQWiG

13-07-2012

Since the start of 2012, a new drug - rilpivirine from US health care giant Johnson & Johnson (NYSE:…

Anti-viralsEuropeEvipleraJohnson & JohnsonPharmaceuticalPricingRegulationrilpivirine

US patients get faster access to more cancer drugs than Europeans, says Tufts

11-07-2012

Cancer patients in the USA get faster access to more oncology drugs to treat their disease than patients…

BiotechnologyEuropeHealthcareNorth AmericaOncologyPharmaceuticalPricingRegulation

Australia's health care regulations struggle to keep up with population aging

10-07-2012

The growing elderly population and its associated disease burden add to the economic challenges faced…

Asia-PacificHealthcareMarkets & MarketingPharmaceuticalPricingRegulation

NICE draft guidance continues negative on Roche's Avastin for metastatic breast cancer

06-07-2012

Final draft guidance published today (July 6) by the UK's drugs watchdog the National Institute for Health…

AvastinEuropeOncologyPharmaceuticalPricingRegulationRoche

New Zealand agrees to fund Iressa but amends Tarceva use

05-07-2012

New Zealand's pharmaceutical management agency PHARMAC has approved the proposal to fund AstraZeneca's…

Asia-PacificAstraZenecaIressaOncologyPharmaceuticalPricingRegulationRocheTarceva

Germany's IQWiG finds no proof of added benefit for AstraZeneca's Caprelsa in thyroid cancer

05-07-2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit…

AstraZenecaCaprelsaEuropeOncologyPharmaceuticalPricingRegulation

Gilead files elvitegravir and cobicistat with FDA; AHF plea on Quad pricing

29-06-2012

US biotech firm Gilead Sciences (Nasdaq: GILD), world's largest maker of HIV drugs, has submitted a New…

Anti-viralsBiotechnologycobicistatelvitegravirGilead SciencesNorth AmericaPricingQuadRegulation

Australian patients to benefit from new PBS listings; OTC reforms

26-06-2012

The listing of 11 prescription medicines on the Australian Pharmaceutical Benefits Scheme (PBS) has been…

Asia-PacificBiotechnologyHealthcarePharmaceuticalPricingRegulation

Issues to be navigated to unleash full potential of stem cell therapies

18-06-2012

Pharmaceutical, biotech and medical device companies are showing increased interest in stem cell research…

BiotechnologyPharmaceuticalPricingRegulationResearch

European generics trade group urges addressing medicines affordability and availability risks

17-06-2012

With pensioners set to represent over 60% of the working population by 2060 in Europe, the pharmaceutical…

EuropeGenericsHealthcarePricingRegulation

UK's NICE denies NHS access to Roche melanoma drug Zelboraf

15-06-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued draft guidance…

EuropeOncologyPharmaceuticalPricingRegulationRocheZelboraf

Australia's PIC reports to Ministers on treatment and reimbursement of similar biologics

14-06-2012

The Australian Pharmaceuticals Industry Council (PIC), with industry group members AusBiotech, Medicines…

Asia-PacificBiotechnologyGenericsPharmaceuticalPricingRegulation

226 to 250 of 329 results

Back to top